Kaohsiung Medical University Hospital, Center for Cancer Research, Kaohsiung Medical University, Kaohsiung; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Hannover, Germany; Division of Gastroenterology and Hepatology, Toronto General Hospital, Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
ESMO Open. 2024 Aug;9(8):103647. doi: 10.1016/j.esmoop.2024.103647. Epub 2024 Aug 6.
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer (BTC), published in late 2022 were adapted in December 2023, according to established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with BTC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with BTC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and the Taiwan Oncology Society (TOS). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different regions of Asia. Drug access and reimbursement in the different regions of Asia are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with BTC across the different countries and regions of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices and molecular profiling, as well as age and stage at presentation. Attention is drawn to the disparity in the drug approvals and reimbursement strategies, between the different countries.
2022 年底，根据既定的标准方法，对欧洲肿瘤内科学会（ESMO）发布的胆道癌（BTC）诊断、治疗和随访临床实践指南进行了改编，以制定针对亚洲 BTC 患者管理的泛亚改编（PAGA）ESMO 共识指南。本文呈现的改编指南代表了亚洲 BTC 治疗专家小组的共识意见，这些专家代表了中国肿瘤学会（CSCO）、印度尼西亚肿瘤学会（ISHMO）、印度肿瘤学会（ISMPO）、日本肿瘤学会（JSMO）、韩国肿瘤学会（KSMO）、马来西亚肿瘤学会（MOS）、菲律宾肿瘤学会（PSMO）、新加坡肿瘤学会（SSO）、中国台湾肿瘤学会（TOS）和泰国肿瘤学会（TSCO）等亚洲国家和地区的肿瘤学会。投票是基于科学证据进行的，独立于亚洲不同地区当前的治疗实践、药物准入限制和报销决策。亚洲不同地区的药物准入和报销在本文中分别进行了讨论。其目的是为亚洲不同国家和地区的 BTC 患者管理的优化和协调提供指导，同时借鉴西方和亚洲试验提供的证据，同时尊重筛查实践和分子谱的差异，以及就诊时的年龄和分期。提请注意，不同国家之间在药物批准和报销策略方面存在差异。
